Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.
Ontology highlight
ABSTRACT: Glioblastoma is an immunosuppressive, deadly brain tumor. IGFBP2, a circulating biomarker for cancer diagnosis and a potential immunotherapeutic target, is attracting more and more attention from oncologists and clinicians. Thus, it is urgent to thoroughly investigate the immune biological process of IGFBP2 to understand tumor immune complexity and provide potential evidence for anti-IGFBP2 therapy. Through authoritative public databases, we enrolled a total of 2447 glioma samples with gene expression profiles. Then, the clinical characteristics and immunosuppressive status of IGFBP2 in the glioma samples were analyzed. Immunohistochemical staining detected the expression of immunosuppressive biomarkers. We found that IGFBP2 expression was upregulated in high-grade glioma and GBM and downr
SUBMITTER: Cai J
PROVIDER: S-EPMC5927515 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
ACCESS DATA